Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement.
Diffuse large B-cell lymphoma (DLBCL), the most common type of human immunodeficiency virus (HIV)-related lymphoma, is associated with a high risk of central nervous system (CNS) involvement.
APA
Ji Y, Gao J, et al. (2025). Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement.. Frontiers in oncology, 15, 1699475. https://doi.org/10.3389/fonc.2025.1699475
MLA
Ji Y, et al.. "Case report of two patients with refractory HIV-related B-cell lymphoma treated with the monoclonal antibody glofitamab for secondary central nervous system involvement.." Frontiers in oncology, vol. 15, 2025, pp. 1699475.
PMID
41783646
Abstract
Diffuse large B-cell lymphoma (DLBCL), the most common type of human immunodeficiency virus (HIV)-related lymphoma, is associated with a high risk of central nervous system (CNS) involvement. Studies have shown that CD20×CD3 bispecific antibodies have significant therapeutic efficacy in refractory B-cell lymphoma. Preliminary reports indicate that the monoclonal antibody glofitamab can penetrate the blood-brain barrier, inducing clinical responses in CNS DLBCL patients by activating T lymphocytes. This report presents preliminary clinical evidence on the use of glofitamab in HIV-positive patients with secondary CNS lymphoma.
같은 제1저자의 인용 많은 논문 (5)
- Corrigendum to "Xiaoai Jiedu recipe reduces cell survival and induces apoptosis in hepatocellular carcinoma by stimulating autophagy via the AKT/mTOR pathway" [J. Ethnopharmacol. 339 (2025) 119135].
- Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer.
- Persistent Gene Activation as a Molecular Signature of Ulcerative Colitis Progression to Colorectal Cancer.
- Multi-omics profiling of sodium-overload (NECSO) programs identifies NEK8 as a central driver of colorectal cancer progression through single-cell and spatial transcriptomics.
- Breathomics profiling facilitates personalized screening for colorectal cancer.